Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients.
Xiang-Na ZhaoYue YouXiao-Ming CuiHui-Xia GaoGuo-Lin WangSheng-Bo ZhangLin YaoLi-Jun DuanKa-Li ZhuYu-Ling WangLi LiJian-Hua LuHai-Bin WangJing-Fang FanHuan-Wei ZhengEr-Hei DaiLu-Yi TianMai-Juan MaPublished in: Signal transduction and targeted therapy (2021)
While some individuals infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present mild-to-severe disease, many SARS-CoV-2-infected individuals are asymptomatic. We sought to identify the distinction of immune response between asymptomatic and moderate patients. We performed single-cell transcriptome and T-cell/B-cell receptor (TCR/BCR) sequencing in 37 longitudinal collected peripheral blood mononuclear cell samples from asymptomatic, moderate, and severe patients with healthy controls. Asymptomatic patients displayed increased CD56briCD16- natural killer (NK) cells and upregulation of interferon-gamma in effector CD4+ and CD8+ T cells and NK cells. They showed more robust TCR clonal expansion, especially in effector CD4+ T cells, but lack strong BCR clonal expansion compared to moderate patients. Moreover, asymptomatic patients have lower interferon-stimulated genes (ISGs) expression in general but large interpatient variability, whereas moderate patients showed various magnitude and temporal dynamics of the ISGs expression across multiple cell populations but lower than a patient with severe disease. Our data provide evidence of different immune signatures to SARS-CoV-2 in asymptomatic infections.
Keyphrases
- sars cov
- single cell
- end stage renal disease
- newly diagnosed
- immune response
- ejection fraction
- chronic kidney disease
- respiratory syndrome coronavirus
- poor prognosis
- nk cells
- peripheral blood
- stem cells
- gene expression
- genome wide
- mesenchymal stem cells
- toll like receptor
- signaling pathway
- tyrosine kinase
- case report
- inflammatory response